» Articles » PMID: 31671085

Update: Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injuries - United States, October 2019

Abstract

CDC, the Food and Drug Administration, state and local health departments, and other public health and clinical stakeholders are investigating a national outbreak of electronic-cigarette (e-cigarette), or vaping, product use-associated lung injury (EVALI) (1). As of October 22, 2019, 49 states, the District of Columbia (DC), and the U.S. Virgin Islands have reported 1,604 cases of EVALI to CDC, including 34 (2.1%) EVALI-associated deaths in 24 states. Based on data collected as of October 15, 2019, this report updates data on patient characteristics and substances used in e-cigarette, or vaping, products (2) and describes characteristics of EVALI-associated deaths. The median age of EVALI patients who survived was 23 years, and the median age of EVALI patients who died was 45 years. Among 867 (54%) EVALI patients with available data on use of specific e-cigarette, or vaping, products in the 3 months preceding symptom onset, 86% reported any use of tetrahydrocannabinol (THC)-containing products, 64% reported any use of nicotine-containing products, and 52% reported use of both. Exclusive use of THC-containing products was reported by 34% of patients and exclusive use of nicotine-containing products by 11%, and for 2% of patients, no use of either THC- or nicotine-containing products was reported. Among 19 EVALI patients who died and for whom substance use data were available, 84% reported any use of THC-containing products, including 63% who reported exclusive use of THC-containing products; 37% reported any use of nicotine-containing products, including 16% who reported exclusive use of nicotine-containing products. To date, no single compound or ingredient used in e-cigarette, or vaping, products has emerged as the cause of EVALI, and there might be more than one cause. Because most patients reported using THC-containing products before symptom onset, CDC recommends that persons should not use e-cigarette, or vaping, products that contain THC. In addition, because the specific compound or ingredient causing lung injury is not yet known, and while the investigation continues, persons should consider refraining from the use of all e-cigarette, or vaping, products.

Citing Articles

Exploring the Practice of Dual Vaping: Health Risks and Behavioral Patterns in Nicotine and Cannabis E-Cigarette Users.

Vaccari Bongetta G, Ferreira Franca R, Pozzolo Pedro M, Leopoldo K, Florence L, Blaas I Brain Sci. 2025; 15(2).

PMID: 40002430 PMC: 11853364. DOI: 10.3390/brainsci15020097.


Social Media Exposure and Other Correlates of Increased e-Cigarette Use Among Adolescents During Remote Schooling: Cross-Sectional Study.

Pravosud V, Ling P, Halpern-Felsher B, Gribben V JMIR Pediatr Parent. 2024; 7:e49779.

PMID: 39432716 PMC: 11515927. DOI: 10.2196/49779.


Effects of E-Cigarettes on the Lung and Systemic Metabolome in People with HIV.

Zaparte A, Christopher C, Arnold C, Richey L, Castille A, Mistretta K Metabolites. 2024; 14(8).

PMID: 39195530 PMC: 11356516. DOI: 10.3390/metabo14080434.


Marketing of nicotinamide as nicotine replacement in electronic cigarettes and smokeless tobacco.

Jabba S, Jordt S Tob Prev Cessat. 2024; 10.

PMID: 39132445 PMC: 11295357. DOI: 10.18332/tpc/187767.


Cross-State Border Nicotine Vaping Products Purchase-Early Evidence From State Emergency Sales Restrictions in 2019.

Cheng K, Liber A, Levy D Nicotine Tob Res. 2024; 26(8):1007-1013.

PMID: 38297975 PMC: 11519049. DOI: 10.1093/ntr/ntae017.


References
1.
Ghinai I, Pray I, Navon L, OLaughlin K, Saathoff-Huber L, Hoots B . E-cigarette Product Use, or Vaping, Among Persons with Associated Lung Injury - Illinois and Wisconsin, April-September 2019. MMWR Morb Mortal Wkly Rep. 2019; 68(39):865-869. PMC: 6776374. DOI: 10.15585/mmwr.mm6839e2. View

2.
Perrine C, Pickens C, Boehmer T, King B, Jones C, DeSisto C . Characteristics of a Multistate Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019; 68(39):860-864. PMC: 6776378. DOI: 10.15585/mmwr.mm6839e1. View

3.
Siegel D, Jatlaoui T, Koumans E, Kiernan E, Layer M, Cates J . Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury - United States, October 2019. MMWR Morb Mortal Wkly Rep. 2019; 68(41):919-927. PMC: 6802682. DOI: 10.15585/mmwr.mm6841e3. View

4.
Lewis N, McCaffrey K, Sage K, Cheng C, Green J, Goldstein L . E-cigarette Use, or Vaping, Practices and Characteristics Among Persons with Associated Lung Injury - Utah, April-October 2019. MMWR Morb Mortal Wkly Rep. 2019; 68(42):953-956. PMC: 6812834. DOI: 10.15585/mmwr.mm6842e1. View